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Abstract
A new approach, termed the Biofield test, may have the potential to augment the process of diagnosing breast cancer. This 
technique is based on the analysis of skin surface electrical potentials measured by an array of specially designed sensors which 
are placed on the breasts. Measurements are recorded noninvasively and then analyzed using pattern recognition algorithms to 
produce an immediate and objective assessment of breast tissue in vivo. Initial clinical trials suggest that the test can achieve a 
sensitivity of approximately 90% and a specificity of 40— 50%, which indicates that the test might be useful for excluding cancer 
when it is, in fact, absent. Although research to date has focused on the differential diagnosis of suspicious breast lesions, future 
applications could include breast cancer screening, close surveillance and diagnosis of recurrent cancers in breasts previously 
treated with conservative therapy, and monitoring the effectiveness of breast cancer therapies, Improvements and new applications 
are expected to occur as additional research and validation in actual clinical settings is performed. Copyright © 1997 Elsevier 
Science Ireland Ltd.
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1. Introduction
The detection and diagnosis of breast cancer can be 
represented by a three-tiered model of breast disease 
management encompassing screening, diagnosis, and 
disease staging (Fig. 1). The ultimate objective of 
screening is to reduce mortality and there exists reason­
able agreement that mammography screening programs
* Corresponding author. Tel.: -Hi 770 7408180; fax: + 1  770 
7401832.
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can reduce mortality by about 30% for women aged 50 
or over [1,2], Physical examination is the other method 
by which breast cancers are initially discovered, al­
though it is more difficult to demonstrate a mortality 
reduction once a malignancy is palpable. In order for 
screening to achieve a reduction in mortality, approxi­
mately 3-10%  of patients are recalled for additional 
evaluation.
Once an abnormality has been detected by screening 
or physical examination, diagnosis o f the abnormality 
occurs, as represented in the second stage of the model. 
A primary objective at this point is to localize and 
characterize the suspicious lesion so that a decision to 
biopsy can be made. Many approaches have been 
adopted for this purpose including ultrasound, fine 
needle aspiration (FNA) biopsy and magnetic reso­
nance (M RI) scanning. Nevertheless, about 30-50% of 
the open biopsies performed in women over age 50 at 
specialized European centers are found to be benign, 
and this number is higher in younger women and in 
North America, where the ratio of benign to malignant 
biopsies is abo.ut 4:1 [3].
The final tier of the model, disease staging, involves a 
tissue sample to determine disease management from 
the perspective of prescribing appropriate treatment. 
However, because the aforementioned techniques have 
limitations, the diagnostic phase in many cases is com­
pleted only when a biopsy specimen is subjected to 
histopathological analysis.
Despite advances made in detecting and diagnosing 
breast disease, there is still a 10-30% false negative rate 
resulting in interval cancers [4,5], and an excessive 
amount of expense, physician concern and patient anx­
iety over false positives resulting from the screening and 
diagnostic process,
A new approach, termed the Biofield test, may have 
the potential to augment the process of diagnosing 
breast cancer. This technique is based on the analysis of 
skin surface electrical potentials measured by an array 
of specially designed sensors which are placed on the 
breasts. The unit of measurement is in millivolts (mV), 
a readily quantifiable biophysical unit of potential en­
ergy which can be recorded noninvasively and then 
algorithmically processed to produce an immediate and 
objective assessment of breast tissue in vivo. The infor­
mation from the test can then be used as an index of 
abnormal proliferation which could aid in the detection 
and diagnosis of neoplastic activity.
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2. Underlying mechanisms of the technique
Normal epithelial cells, including those that line 
breast ducts, are electrically polarized by an ionic gradi­
ent across the cell membrane [6]. The charge gradient is 
asymmetric between the apical and basolateral cell
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Fig. 2. Electrical gradients in breast epithelium.
membranes and is known as the transepithelial electri­
cal potential [7,8]. This concept is illustrated in Fig, 2, 
which shows the electrical gradients across normal ep­
ithelium which lines the terminal ductal lobular units of 
the breast. The electrical gradient across the membrane 
is maintained by the different permeabilities to ions 
(predominantly K + and Na + ) and water at the lumi­
nal aspect of the duct as compared to the abluminal 
side and results in a transepithelial potential difference 
of about 30 mV, i.e. the net difference of the apical 
potential ( — 70 mV) and the basolateral potential ( — 
100 mV). The vectorial transport of ions which main­
tain the transepithelial potential difference is facilitated 
by the tight junctions which divide the cell membrane 
into distinct apical and basolateral domains. As epithe­
lial cells divide, the charge gradient across the epithelial 
layer is dissipated, resulting in electrical depolarization. 
When epithelial cells in certain areas of the breast 
divide more rapidly than those in other areas of the 
breast, as when a cancer develops, it results in a pocket 
of relative depolarization which can produce a differen­
tial in electrical potential at the skin surface. These 
differentials have been measured using a specially de­
signed sensor array and measurement device [9-11].
3. Field carcinogenesis
One question which arises when a new technology for 
breast cancer detection is introduced is whether it can 
provide useful information for small lesions as well as 
large ones. It is generally accepted that the effectiveness 
of most diagnostic tests decreases as lesion size de­
creases, How then is it possible that electropotential 
measurements made at the skin surface can detect 
abnormal proliferation associated with a nonpalpable 
malignant lesion within the breast? The available evi­
dence suggests that cancer develops within a back­
ground of dysregulated proliferation encompassing a 
field which contains and extends beyond the tumor 
itself [12-14]. Preliminary studies which employ inva­
sive needle electrodes indicate that the region of electri­
cal depolarization extends to the skin surface in 
quadrants of the breast which harbor a malignancy 
(Davies R.J., personal communication).
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4. Noninvasive measurement of breast electropotentials
Accurate measurement of skin surface electropoten­
tials requires use of a specialized device and sensor 
system [10], The sensors which have been developed for 
this application are extremely accurate tranducers, low 
in noise and electrical impedance. Each single-use sen­
sor is pre-loaded with a specially designed conductive 
gel. The device utilizes microprocessor technology for 
control of signal sampling, filtering, and data process­
ing. The device also contains a functional test unit 
which allows the technician or service personnel to 
verify signal integrity inclusive of the device and cable
system.
A key aspect of this technology is the ability to 
sample electrical potentials concurrently from an array 
of many sensors placed on the breast. This allows 
multiple comparisons between sensor sites for the detec­
tion of abnormal proliferation which reveal regions or 
pockets of relative depolarization on the surface of the 
breast, analogous to pockets of low and high pressure 
systems seen on weather maps. In both cases, it is the 
relative difference in energy over a curved surface 
which is informative.
The technology in its present form confers a number 
of inherent advantages. These include:
(1) The test is completely noninvasive and there is no 
pain associated with the procedure.
(2) There is no exposure to ionizing radiation or other 
energy.
(3) The test is simple to implement and can be per­
formed by a technician.
(4) Conducting the test takes about 15 min and the 
result is available immediately.
(5) The test can be repeated as often as needed.
(6) The test result is objective and does not require an 
expert for interpretation.
(7) The test, when widely available, should be cost 
effective.
Because the test is noninvasive, simple to use, and is 
expected to be cost effective, it eventually could be 
integrated into a variety of health care settings where 
breast evaluation occurs and may provide adjunctive 
information for assisting in the resolution of screen 
detected abnormalities or suspicious palpable lesions: 
In Europe, there may be up to 8 million women each 
year who would benefit from a more accurate and 
convenient method of diagnosis of suspicious breast 
lesions, the majority of which (over 7 million) present 
with palpable findings.
5. Test procedure
r
The test procedure superficially resembles that of an 
electrocardiogram. However, the informative signal is a
result of selective filtering of skin surface potentials to 
identify the electrical characteristics associated with 
dysregulated proliferation. The patient lies supine and 
the location of the lesion is identified either by palpa­
tion or, if the lesion is nonpalpable, by estimation based 
on the mammogram. Each of the 16 measurement 
sensors is labeled with a visual code to aid in proper 
positioning relative to the location o f the lesion. The 
technician first places the appropriate sensor on the 
skin over the center o f the suspicious lesion. Four other 
designated sensors are then placed in medial, lateral, 
superior, and inferior positions relative to the sensor 
placed over the center o f  the lesion. Two sensors are 
then placed in the center o f  the two quadrants adjacent 
to that which contains the suspicious lesion and an 
additional sensor is placed in the axilla.
The pattern of sensor placement is then reproduced 
in a mirror-image pattern  on the opposite breast. In 
this way, the opposite breast serves as a control for 
evaluation of asymmetry between the two breasts. 
Lastly, reference sensors are placed on each of the two 
palms. All electropotential measurements are made rel­
ative to the two reference sensors.
Once the sensors are positioned, a period of time is 
allowed for the conductive gel to equilibrate with the 
skin. In the early studies, a period o f  10 min was 
allowed for equilibration, bu t more recent data suggest 
that this could be reduced without affecting perfor­
mance. After equilibration, signal acquisition occurs 
and takes approximately 1 min. The device is p ro ­
grammed to alert the technician should spurious m ea­
surements occur, requiring a re-test.
6. Initial observations from early clinical trials
Clinical trials conducted in Europe, the US, and 
Japan have focused primarily on the differential diag­
nosis of previously localized breast lesions. F o r this 
application, a standard array of eight sensors per breast 
has been studied (Fig. 3). In addition, the effectiveness
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Fig. 3. Sensor placement for standard diagnostic array.
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Table 1
Sites participating in European multicentre study
fi.O
Institut Gustave-Roussy, Paris (Villejuif),
France
Institut Montpellierain D'Imagerie Medico-Bi- 
ologique (IM1M), Montpellier, France 
National Expert and Training center for Breast 
cancer Screening, Nijmegen, The Netherlands 
University o f Hamburg, Hamburg, Germany
Esslingen Hospital, Esslingen, Germany
Guy’s Hospital, London, UK
Istituto Europeo Di Oncologia, Milan, Italy
Istituto Nazionale per lo Studio e la cura dei 
Tumori, Milan, Italy
Dr. Daniel 
Vanel 
Prof. J.L, 
Lamarque 
Dr, Roland 
Holland 
Prof. H.J.
Frisch bier 
Prof. Volker 
Barth
Prof, Ian Fenti- 
man
Dr. Virgilio Sac 
chini
Dr. Mirella 
Merson
of larger arrays for breast cancer screening have been 
explored in preliminary studies which are discussed 
later in this paper.
The initial diagnostic studies conducted in Europe 
and the US indicated that breast cancers produced 
significantly greater electropotential differentials, both 
within the symptomatic breast and between the two 
breasts as compared to benign lesions [9,11,15]. Because 
more than one electropotential differential provides 
discriminative information, diagnosis may be enhanced 
by combining the most informative differentials into 
pattern recognition algorithms [16,17].
7. Clinical trials approach
In the most recently analyzed study, conducted at 
eight centres in five European countries, the compari­
son between the Biofield result and histopathology was 
evaluated for 661 patients using a prospective algorithm 
under double-blinded conditions. The participating cen­
ters are listed in Table 1. One advantage of this study 
was the utilization of a blinded pathology review, which 
produced a relatively consistent evaluation of tissue 
proliferation for each tested lesion. A manuscript de­
scribing the results of this study is currently in prepara­
tion, A similar study conducted at six centres in the US 
is currently undergoing analysis.
In the study protocols, patients undergo the Biofield 
test prior to open biopsy. The result of the Biofield test 
is then compared with that of histopathology to deter­
mine accuracy o f the test. Analysis of the clinical 
studies to date indicates that the Biofield test can 
achieve a sensitiviy o f about 90%, and that this sensitiv­
ity is maintained for small and nonpalpable cancers. In 
addition, the test identifies about 90% of atypical and in 
situ lesions as positive. It cannot as yet be determined 
whether the test is capable o f discriminating invasive
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Fig. 4. European multicentrc study. Electropotential differentials o\ 
benign, borderline and malignant lesions. Mean values with standarc 
error bars.
cancers from noninvasive cancers or atypical lesions. 
Specificity of the test approaches 50% for nonprolifera­
tive benign lesions and is somewhat lower for prolifera­
tive benign lesions. As in previous studies, cancers in 
the European multicenter study produced significantly
4
greater electropotential differentials than benign lesions 
(Fig. 4). Borderline (atypical and in situ) lesions tend to 
produce differentials intermediate between benign le­
sions and invasive cancers.
One important measure of the clinical utility of a 
diagnostic test is the negative predictive value, or the 
probability that a negative test result indicates that the 
patient is free of disease. This measure is calculated 
using the sensitivity and specificity of the test along 
with the prevalence of disease in the population for 
which the test is intended.
A test which can achieve a sensitivity of 90% and a 
specificity of 40-50% has a negative predictive value of 
about 96% in a population with a cancer prevalence of 
15%. Negative predictive value increases as prevalence 
decreases (Table 2). With sufficient confidence that a 
negative test indicates that the patient is free of disease, 
the specificity comes to represent the percentage of 
other diagnostic tests which may be avoided. Of course, 
as with any new diagnostic test, the Biofield result
Table 2
Negative predictive value as a function of prevalence
Cancer risk (prevalence) NPV with negative Biofield*
10% 97.3%
15% 95.8%
2 0 % 94.1%
* Based on 90% sensitivity and 40% specificity.
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Fig. 5. Sensor placement for screening array.
should be interpreted within the context of other avail­
able patient information and test results in the clinical 
decision making process*
evaluate tissue proliferation before, during, and after 
cycles of therapy. There are two indirect lines of evi­
dence that support the used o f the Biofield technology 
for the assessment of tissue proliferation. The first line 
of evidence comes from the multicenter trials, in which 
it was found that proliferative and atypical benign 
lesions produced greater electropotential differentials 
than nonproliferative benign lesions. The second line of 
evidence is from studies in which higher electropotential 
differentials were found to correlate with the thymidine 
labeling index of excised malignant tumors, an in vitro 
measure of cell proliferation sometimes used for prog­
nosis [15].
Although the technology described in this paper is 
still in its early stages» a potential positive impact has 
been demonstrated under rigorous clinical trial p ro to ­
cols, Improvements and new applications would be 
expected to occur as additional research and validation 
in actual clinical settings is performed.
8. Future applications of the technology
As previously described, most of the clinical research 
has focused on evaluating effectiveness of the test for 
the differential diagnosis of localized suspicious breast 
lesions.
A next step would be further development and clini­
cal assessment of the technology as a new modality for 
breast cancer screening. For this application, additional 
sensors would be utilized to allow measurement of 
electropotentials independent of lesion location and for 
asymptomatic women (Fig. 5). The objective would be 
identification of high risk patients by detecting abnor­
mal levels of relative depolarization in the breasts, as 
reflected by higher electropotential differentials. These 
patients could then be referred for imaging or other 
tests. Initial pilot studies using a nondirected, or screen- 
ing type array indicate that cancers produce higher 
differentials than benign lesions or unbiopsied, ostensi­
bly normal tissue [18].
Another potential application of the technology may 
be for the diagnosis of recurrent cancer. In the irradi­
ated breast for example, mammography has been 
shown to have a sensitivity of only 64% for recurrent 
carcinoma in patients who previously had undergone 
conservative surgery [19]. The Biofield diagnostic array 
could be utilized for these cases because the region of 
suspicion, i.e. the site of the previous cancer, is iden­
tifiable. Pilot studies are currently under way in Europe 
to determine the potential effectiveness of the Biofield 
test for this application.
Monitoring the effectiveness of therapy may be an­
other potentially useful application of the technology. 
Currently, it is difficult to assess the effectiveness of 
therapy prior to mortality reduction endpoints in ran­
domized trials. An alternative approach might be to
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